Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

NDA FilingBezuclastinibPositive

AI Analysis

Summary

Cogent Biosciences announced submission of a New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis, representing a significant regulatory milestone in the drug's development.

Importance:7/10

Sentiment:

0.50

NDA submissionregulatory milestonesystemic mastocytosisCogent Biosciences

Related Companies

$COGT

Read the original article

Published by yahoo_finance on June 30, 2026 12:00 PM

Read Original